# A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Source: https://onco.cc/trials/nct06038578/  
OnCo record `nct06038578` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TRK-950 and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Toray Industries, Inc, now recruiting.

## Summary

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer is a phase 2 interventional study registered as NCT06038578 by Toray Industries, Inc, with 146 participants planned, started 2023-10-04 and due to reach its primary completion in 2026-06-30. Interventions recorded: TRK-950, Ramucirumab and Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06038578
- Phase: 2
- Setting: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
- Sponsor: Toray Industries, Inc
- Enrolled: 146

## Sources

- ClinicalTrials.gov NCT06038578: https://clinicaltrials.gov/study/NCT06038578

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [TRK-950](https://onco.cc/drugs/trk-950/)

---
JSON: https://onco.cc/api/v1/entities/nct06038578.json